Featured Post

Latest Gold News

Economic power could shift further East with Hong Kong gold exchange Russian investment bank sees $1,400 gold by end of 2017 Weak CPI...

Monday, November 14, 2011

Amgen (AMGN) (MWE) (NBY) (NLY) (ALIM) (AMLN) Ratings, Price Targets

Amgen, Inc. (AMGN), MarkWest Energy Partners (MWE), Novabay Pharmaceutic (NBY), Annaly Capital Management, Inc. (NLY), Alimera Sciences Inc. (ALIM) and Amylin Pharma (AMLN) ratings and price targets.

Leerink downgraded Amgen, Inc. (AMGN) from an “Outperform” rating to a “Market Perform” rating.

Wells Fargo & Co. (NYSE:WFC) upgraded MarkWest Energy Partners (MWE) from a “Market Perform” rating to an “Outperform” rating.

LifeTech Capital downgraded Novabay Pharmaceutic (NBY) to a “Neutral” rating. They have a price target of $1.25 on the company.

JPMorgan Chase & Co. (NYSE:JPM) initiated coverage on Annaly Capital Management, Inc. (NLY). They placed an “Overweight” rating and a price target of $18.00 on the company.

Citigroup (NYSE:C) downgraded Alimera Sciences Inc. (ALIM) from a “Buy” rating to a “Neutral” rating.

Robert W. Baird upgraded Amylin Pharma (AMLN) from a “Neutral” rating to an “Outperform” rating. They have a price target of $15.00 on the company, up from $13.00.

No comments: